

Accepted Manuscript

Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis

Sandeep K. Gupta , Joanne M. Vitanza , Margaret H. Collins



PII: S1542-3565(14)00804-0

DOI: [10.1016/j.cgh.2014.05.021](https://doi.org/10.1016/j.cgh.2014.05.021)

Reference: YJCGH 53839

To appear in: *Clinical Gastroenterology and Hepatology*

Accepted Date: 22 May 2014

Please cite this article as: Gupta SK, Vitanza JM, Collins MH, Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis, *Clinical Gastroenterology and Hepatology* (2014), doi: 10.1016/j.cgh.2014.05.021.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in *Clinical Gastroenterology and Hepatology* are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.

Title: Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis

Short Title: Oral Budesonide for Eosinophilic Esophagitis

Authors: Sandeep K. Gupta,¹ Joanne M. Vitanza,² Margaret H. Collins,³

¹Section of Pediatric Gastroenterology, Hepatology and Nutrition, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana

²Meritage Pharma, Inc., San Diego, California

³Department of Pathology and Laboratory Medicine, University of Cincinnati, Division of Pathology & Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Support: This study was sponsored by Meritage Pharma, Inc. (ClinicalTrials.gov number NCT00762073).

Abbreviations: AE, adverse event; CSS, Clinical Symptom Score; DSQ, Dysphagia Symptom Questionnaire; EoE, eosinophilic esophagitis; EOT, end of treatment; FDA, Food and Drug Administration; GER, gastroesophageal reflux; GERD, gastroesophageal reflux disease; HPF, high-power field; OBS, oral budesonide suspension; PEER, Pediatric Eosinophilic Esophagitis Research; PPI, proton pump inhibitor; PRO, patient-reported outcome; US, United States

Correspondence:

Sandeep K. Gupta, M.D.

Download English Version:

<https://daneshyari.com/en/article/3282389>

Download Persian Version:

<https://daneshyari.com/article/3282389>

[Daneshyari.com](https://daneshyari.com)